Irinot 100mg Injection

This formulation is intended for intravenous administration under strict medical supervision. The dosage and treatment schedule should be individualized based on patient tolerance, tumor response, and clinical guidelines. Common adverse effects include neutropenia, diarrhea, nausea, vomiting, and fatigue, which require careful monitoring and supportive care. Irinot 100mg Injection is contraindicated in patients with severe bone marrow suppression or hypersensitivity to Irinotecan or its components.

Caution is advised in patients with impaired hepatic function, as metabolism and clearance of Irinotecan may be affected. Drug interactions may occur with agents that affect cytochrome P450 enzymes, necessitating dose adjustments. This product should be used as part of a comprehensive oncology treatment regimen, often in combination with other chemotherapeutic agents. Proper handling and disposal procedures must be followed to minimize exposure risks to healthcare personnel.